Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice
Clin. transl. oncol. (Print)
; 20(7): 862-869, jul. 2018. tab, graf
Artigo
em Inglês
| IBECS
| ID: ibc-173637
Biblioteca responsável:
ES1.1
Localização: BNCS
ABSTRACT
Introduction:
This study aimed to describe the efficacy of fulvestrant 500 mg in postmenopausal women with estrogen receptor (ER)-positive advanced/metastatic breast cancer who had disease progression after receiving anti-estrogen therapy in clinical practice, getting real-world data. Materials andmethods:
Multicenter, retrospective, observational study conducted in Spain. Postmenopausal women with locally advanced/metastatic ER-positive breast cancer who received treatment with fulvestrant 500 mg after progression with a previous anti-estrogen therapy were eligible. The primary endpoint was progression-free survival (PFS); secondary endpoints were overall survival (OS), clinical benefit rate (CBR), duration of clinical benefit (DoCB), and safety profile.Results:
A total of 263 women were evaluated (median age, 65.8 years). At a median follow-up of 21.5 months, median PFS and OS were 10.6 and 43.2 months, respectively. PFS according to 1st, 2nd, 3rd, and ≥ 4th lines were 11.5, 10.6, 9.9, and 8.5 months, respectively (p = 0.0245). PFS in patients with visceral involvement was 10 months vs 10.6 months in patients without visceral involvement (p = 0.6604), 9.6 months in patients with high Ki67 vs 10 months in patients with low Ki67 (p = 0.7224), and 10.2 months in HER2+ patients vs 10.3 months in HER2− patients (p = 0.6809). The CBR was 56.5% and the DoCB was 18.4 months. The most frequently adverse events were injection site pain (10.3%) and musculoskeletal disorders (7.6%).Conclusions:
Fulvestrant 500 mg administered in clinical practice was shown to be effective (PFS, 10.6 months; CBR, 56.5%) and well tolerated, in accordance with previous trialsRESUMEN
No disponible
Buscar no Google
Coleções:
Bases de dados nacionais
/
Espanha
Base de dados:
IBECS
Assunto principal:
Neoplasias da Mama
/
Carcinoma Lobular
/
Carcinoma Ductal de Mama
Tipo de estudo:
Estudo observacional
Limite:
Feminino
/
Humanos
Idioma:
Inglês
Revista:
Clin. transl. oncol. (Print)
Ano de publicação:
2018
Tipo de documento:
Artigo
Instituição/País de afiliação:
Clínica Benidor/Spain
/
Complejo Hospitalario Universitario/Spain
/
Complejo Universitario Asistencial de León/Spain
/
Complejo Universitario Hospital de Navarra/Spain
/
Hospital Clinic de Barcelona/Spain
/
Hospital Costa del Sol/Spain
/
Hospital Juan Ramón Jiménez/Spain
/
Hospital Nuestra Señora De Valme/Spain
/
Hospital Provincial de Castellón/Spain
/
Hospital Ramón y Cajal/Spain